• Triple-Pathway Inhibition in BRAFV600E Melanoma

  2026-09-12

  The reference study shows that RocA-induced stress in BRAFV600E melanoma activates temporally distinct ERK1/2–EZH2 and AKT1–eIF4E resistance programs. Its central practical finding is that concurrent inhibition of eIF4F, EZH2, and AKT1 can improve responses in RocA- and vemurafenib-resistant models, although the evidence remains preclinical and melanoma-specific.

• Nav1.6–NHE1 Signaling in Glioblastoma

  2026-09-11

  A 2025 Molecular Biology Reports study identifies a functional Nav1.6–NHE1 axis that supports glioblastoma proliferation and migration while sustaining ERK-AKT survival signaling. Its combined genetic and pharmacological design links ion regulation with measurable changes in DNA synthesis, motility, and apoptosis, although validation beyond cultured cell models is still needed.

• Exosomal HMGB1 in Lupus Nephritis Endothelial Injury

  2026-09-11

  The reference study identifies podocyte-derived exosomal HMGB1 as a mechanistic driver of glomerular endothelial cell injury in lupus nephritis through TRIM27 upregulation. Its combined patient, cell, and mouse experiments support exosome release and HMGB1 cargo as experimentally tractable points for dissecting podocyte–endothelial communication.

• Imipenem: Mechanism and Research Applications

  2026-09-10

  Imipenem is a semisynthetic thienamycin antibiotic with broad-spectrum activity against gram-negative and gram-positive bacteria. Its PBP-directed cell-wall mechanism, defined research concentrations, and sepsis animal model findings support antibacterial research while remaining distinct from clinical efficacy claims.

• MK-8745: Reading Aurora A Dependency in Cancer

  2026-09-10

  MK-8745 is a potent, selective Aurora A inhibitor for connecting mitotic disruption with apoptosis and tumor biology. This article uses retinoblastoma evidence to show how target expression, functional dependency, and assay phenotype should be interpreted together.

• Azilsartan (TAK-536) Experimental Workflows

  2026-09-09

  Azilsartan (TAK-536) provides a selective AT1-receptor perturbation strategy for separating renin–angiotensin signaling from broader inflammatory effects. This guide translates reactive astrocyte–microglia findings into practical dosing, controls, readouts, and troubleshooting steps for cardiovascular and neuroinflammation research.

• Angiotensin II Workflows for AAA Research

  2026-09-09

  Build reproducible hypertension, vascular remodeling, and abdominal aortic aneurysm workflows with a defined Angiotensin II stimulus. This guide connects acute receptor signaling and vascular smooth muscle phenotypes with the senescence-gene framework reported in recent AAA research, while separating validated parameters from practical assay recommendations.

• KR-12 Human Antimicrobial Peptide: Bench Workflows

  2026-09-08

  KR-12 combines membrane-targeted antimicrobial activity with anti-biofilm, LPS-neutralizing, and host-response applications in a compact LL-37 fragment. This practical guide covers TFA-salt handling, strain-aware assays, biofilm testing, mammalian-cell controls, copper-variable experiments, and troubleshooting strategies.

• Haloprogin: Applied Antifungal Research Workflows

  2026-09-08

  Haloprogin supports quantitative workflows spanning dermatophyte, Candida, and selected Gram-positive bacterial assays. This guide translates historical MIC/MFC methods and topical infection-model findings into practical setup, formulation, comparison, and troubleshooting decisions.

• Bufalin–STK33 Degradation in Triple-Negative Breast Cancer

  2026-09-07

  The reference study identifies STK33 as a Bufalin-binding protein and connects its destabilization to reduced triple-negative breast cancer growth. By combining target-discovery chemistry, mechanistic protein analyses, animal models, and patient-derived organoids, the work provides a preclinical framework for target-based TNBC research while leaving clinical selectivity and safety unresolved.

• Dual Luciferase Reporter Gene System for MYC2

  2026-09-07

  Learn how the Dual Luciferase Reporter Gene System can turn the tomato MYC2–LBD40/42–CRL3BPM4 model into a testable reporter strategy. This practical, limitation-aware guide explains normalization, sequential chemistry, and when K1136 data support claims about gene expression regulation.

• Nanoparticle mRNA Delivery Reverses Trastuzumab Resistance

  2026-09-05

  The reference study developed a tumor-microenvironment-responsive nanoparticle for systemic PTEN mRNA delivery in trastuzumab-resistant breast cancer. Its results connect pH-triggered nanoparticle uptake, PTEN restoration, PI3K/Akt signaling pathway inhibition, and improved response to trastuzumab, while also highlighting the preclinical constraints of translating this platform.

• TaqI Restriction Endonuclease: Digestion Guide

  2026-09-04

  TaqI Restriction Endonuclease (SKU K3053) provides rapid, sequence-specific cleavage of plasmid DNA, PCR products, and genomic DNA containing the TCGA recognition site. It is intended for scientific research workflows such as DNA mapping and cloning, not for diagnostic or medical use.

• EZ Cap™ Cy5 EGFP mRNA: Assay Guide

  2026-09-04

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) is a Cy5-labeled mRNA reporter that separates cellular cargo uptake from functional EGFP translation. Its Cap1 structure, modified uridine chemistry, and dual fluorescence support quantitative mRNA delivery and translation efficiency assays.

• Cy3 Goat Anti-Human IgG: Assay Design Guide

  2026-09-03

  The Cy3 Goat Anti-Human IgG (H+L) Antibody supports sensitive human IgG detection across fluorescence, tissue, cytometry, and ELISA workflows. This guide focuses on host-species logic, antiviral antibody research, assay controls, and the limits of translating discovery findings into practical detection assays.

8552 records 1/571 page Next 12345 下5页 Last page